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Abstract: 
 
To test the hypothesis that heightened sympathetic outflow precedes and predicts the magnitude 
of the growth hormone (GH) response to acute exercise (Ex), we studied 10 men [age 26.1 ± 1.7 
(SE) yr] six times in randomly assigned order (control and 5 Ex intensities). During exercise, 
subjects exercised for 30 min (0900–0930) on each occasion at a single intensity: 25 and 75% of 
the difference between lactate threshold (LT) and rest (0.25LT, 0.75LT), at LT, and at 25 and 
75% of the difference between LT and peak (1.25LT, 1.75LT). Mean values for peak plasma 
epinephrine (Epi), plasma norepinephrine (NE), and serum GH concentrations were determined 
[Epi: 328 ± 93 (SE), 513 ± 76, 584 ± 109, 660 ± 72, and 2,614 ± 579 pmol/l; NE: 2.3 ± 0.2, 3.9 ± 
0.4, 6.9 ± 1.0, 10.7 ± 1.6, and 23.9 ± 3.9 nmol/l; GH: 3.6 ± 1.5, 6.6 ± 2.0, 7.0 ± 2.0, 10.7 ± 2.4, 
and 13.7 ± 2.2 μg/l for 0.25, 0.75, 1.0, 1.25, and 1.75LT, respectively]. In all instances, the time 
of peak plasma Epi and NE preceded peak GH release. Plasma concentrations of Epi and NE 
always peaked at 20 min after the onset of Ex, whereas times to peak for GH were 54 ± 6 (SE), 
44 ± 5, 38 ± 4, 38 ± 4, and 37 ± 2 min after the onset of Ex for 0.25–1.75LT, respectively. 
ANOVA revealed that intensity of exercise did not affect the foregoing time delay between peak 
NE or Epi and peak GH (range 17–24 min), with the exception of 0.25LT (P < 0.05). Within-
subject linear regression analysis disclosed that, with increasing exercise intensity, change in (Δ) 
GH was proportionate to both ΔNE (P = 0.002) and ΔEpi (P = 0.014). Furthermore, within-
subject multiple-regression analysis indicated that the significant GH increment associated with 
an antecedent rise in NE (P = 0.02) could not be explained by changes in Epi alone (P = 0.77). 
Our results suggest that exercise intensity and GH release in the human may be coupled 
mechanistically by central adrenergic activation. 
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Article: 
 
Although an acute bout of exercise of appropriate intensity will evoke a large increase in serum 
GH concentrations (2,6, 8, 10, 19,21, 23, 29, 33,37, 38, 39, 41,42), few quantitative correlates 
are available to link central nervous-system activation with growth hormone (GH) release to 
greater exercise intensities. We recently reported a linear dose-response relationship between 
exercise intensity and incremental GH release in young men across a wide span of exertional 
intensities beginning below the lactate threshold (LT) (29). On the basis of these data, we 
hypothesized that progressive augmentation of GH release at higher exercise intensities may be 
mediated by antecedent but proportionate changes in neurotransmitter activity. 
 
Epinephrine (Epi), norepinephrine (NE), acetylcholine, GABA, and opioids have been variously 
suggested as plausible neuromodulators of GH release during exercise (13). Our laboratory and 
those of others have reported that, during acute progressively incremental exercise, blood 
catecholamine concentrations rise with increasing exercise intensity (26, 28, 30,40). Such 
observations suggest that heightened central nervous system sympathetic outflow may contribute 
to the GH secretory response to acute exercise. In the present study, we used a series of acute 
exercise bouts of varying intensity, assigned in random order on separate study days, to examine 
the relationship between the simultaneously monitored release of GH and NE or Epi during 
exercise and recovery. This randomized block design was intended to obviate any serial 
confounds otherwise possibly introduced by a schedule of continuously increasing exercise 
intensity in the same setting, and it may also minimize anticipatory confounds. We hypothesized 
that, if increased sympathetic activity is an important mediator of the GH response to exercise 
(e.g., via α2-central adrenergic neurons), greater sympathetic outflow, as reflected peripherally 
by NE and Epi release, should precede in time and correlate in incremental amounts with 
heightened GH secretory responses to exercise. 
 
METHODS 
 
Rationale. The present design uses randomly ordered independent variable-intensity exercise 
sessions conducted at the same time of day in a controlled nutritional context to test the relative 
timing of NE and Epi release and GH secretion in young men. This strategy was intended to limit 
any ad seriatim carryover effects. By imposing a large (sub- vs. supra-LT) range of exercise 
intensities, we explore the relationship, if any, between incremental NE and/or Epi release and 
incremental GH secretion. Individual regression analyses in 10 subjects are used to establish the 
consistency of observed relationships. 
 
Subjects. Ten recreationally active men [mean age, 26 ± 1.1 (SE) yr; mean height, 178 ± 1.7 cm; 
mean weight, 83.4 ± 2.8 kg] provided voluntary written informed consent, as approved by the 
Human Investigation Committee of the University of Virginia Health System, before entering the 
study. Each subject underwent a detailed medical history and physical examination, and no 
subject had a history of pituitary, renal, hepatic, metabolic, or other systemic disease. The 
subjects were nonsmokers, did not abuse alcohol, and were not taking any medication known to 
affect GH secretion. Screening laboratory chemistry revealed normal hematologic, renal, hepatic, 
metabolic, and thyroid function. Subjects refrained from exercise for 24 h before each 
evaluation. An estimate of statistical power was determined a priori for n = 10 with approximate 
statistical power of 85% for detecting a 50% treatment effect of exercise at P = 0.05 by using 
serum GH concentration as the measured response variable. 
 
Experimental design. Each volunteer first completed a treadmill test to assess level of 
cardiovascular fitness and underwent hydrostatic weighing to determine body density at the 
Exercise Physiology Laboratory of the General Clinical Research Center (GCRC). Subjects were 
then evaluated on six separate and randomly ordered occasions, five with exercise and one at 
rest. The admissions were scheduled at least 7 days apart, and no more than two admissions were 
allowed within 2 mo (to ensure that guidelines for blood withdrawal were not exceeded). 
Exercise consisted of 30 min of constant load exercise at a predetermined velocity. Treadmill 
velocity was set at 25 and 75% of the difference between the O2 uptake (V˙o2) at the LT 
andV˙o2 at rest (0.25LT and 0.75LT, respectively), at LT (LT) and at 25% and 75% of the 
difference between the V˙o2 at LT and peakV˙o2(V˙o2 peak) (1.25LT and 1.75LT, respectively), on 
the basis of results obtained during a prior LT andV˙o2 peak protocol (see LT andV˙o2 peak below). 
 
Body composition. Body density was assessed by hydrostatic weighing (20). Each subject was 
weighed in air on an Accu-weigh beam scale accurate to 0.1 kg and subsequently weighed 
underwater on a Chatillon autopsy scale accurate to 10 g. Residual lung volume was measured 
by using an O2-dilution technique (43). The computational procedure of Brozek et al. (1) was 
used to determine percent body fat from body density measurements. 
 
LT and V˙o2 peak. A continuous treadmill (Quinton Q 65 treadmill) exercise protocol with 
increasing velocity until volitional fatigue was used to assess LT and V˙o2 peak. The initial 
velocity was set at 100 m/min with increases in velocity of 10 m/min every 3 min. Open-circuit 
spirometry was used to collect metabolic data (model 2900Z metabolic measurement cart, 
SensorMedics, Yorba Linda, CA). Heart rate was determined via a Marquette Max-1 
electrocardiograph. An indwelling venous cannula was inserted into a forearm vein before 
testing, and blood samples were taken at rest and during the last 15 s of each stage for the 
measurement of blood lactate concentration (2700 Select biochemistry analyzer, Yellow Springs 
Instruments, Yellow Springs, OH). The test was terminated when the subject reached volitional 
exhaustion.V˙o2 peak was chosen as the highestV˙o2 attained. 
 
Determination of LT. The blood lactate-velocity relationship that was obtained from the 
LT/V˙o2 peak protocol was used to estimate the LT. Velocity at LT was determined by plotting 
blood lactate concentration against treadmill velocity and was chosen as the highest velocity 
obtained before the curvilinear increase in blood lactate concentration with increasing velocities. 
An elevation in blood lactate concentration of at least 0.2 mM (the error associated with the 
lactate analyzer) above baseline was required for LT determination.V˙o2 associated with velocity 
LT was then determined (36). 
 
Exercise and control days. Subjects were admitted to the GCRC on the evening before the 
exercise and control studies to allow for adaptation to the unit and a uniform overnight fast. 
Subjects were required to consume their evening meal at or before 1700 and then received a 
standardized snack (500 kcal) at 2000. The nutrient composition of the snack was 55% 
carbohydrate, 15% protein, and 30% fat. Subjects were allowed to consume water ad libitum. To 
avoid possible confounding effects of meals on GH secretion, subjects then fasted until the end 
of the study (15). At 2100, intravenous cannulas were placed bilaterally in each forearm vein. 
 
Subjects remained at the GCRC after eating their snack and were asked to turn lights off by 2300 
(16). Volunteers were awakened at 0600. At this time, basal metabolic parameters were 
measured for 30 min by using a Delta-Trac bedside metabolic unit (SensorMedics, Anaheim, 
CA). Beginning at 0700, blood samples were withdrawn every 10 min until 1300 for later 
measurement of serum GH concentrations. Beginning at 0800, blood samples were withdrawn 
every 20 min until 1300 for later catecholamine analysis. After 2 h of baseline blood sampling, 
subjects began their exercise bout or remained at rest (control). The exercise bout began at 0900 
and continued until 0930. During the exercise bout, blood lactate was also measured every 10 
min. Metabolic data were measured minute-by-minute by using open-circuit spirometry (model 
2900Z metabolic measurement cart, SensorMedics). At the end of the study (1300) subjects were 
fed and discharged from the unit. 
 
GH analysis. GH concentrations in all serum samples (0600–1200) were measured by using a 
recently validated ultrasensitive (0.005 μg/l threshold) chemiluminescence-based assay (Nichols, 
San Juan Capistrano, CA) (7, 18, 35). The chemiluminescent assay detects predominately the 22-
kDa form of GH, with 34% cross-reactivity with 20-kDa GH (methionylated). The median intra-
assay coefficient of variation (CV) for the GH assay was 6.0%, and the interassay CV was 9.9%. 
Secretory data are expressed per unit distribution volume in each subject, thereby mirroring GH 
concentration bathing the target tissue. 
 
Catecholamine analysis. Plasma catecholamine analysis was performed by using a modification 
of the procedure published by Bioanalytic Systems (BAS; LCEC Application Note no. 14). 
Blood samples (4 ml) were collected in Vacutainer tubes containing EDTA and transferred to 
polypropylene tubes containing an EGTA-glutathione stabilizer (20 ml/ml of blood). The 
stabilizer tubes, prepared before the admission, were kept at −70 C until analyzed for 
catecholamine content. 
 
The determination of plasma Epi and NE concentrations was performed by using HPLC with 
electrochemical detection. Plasma samples were thawed on ice and adsorbed to 50 mg of acid-
washed alumina buffered to pH 8.65 with 1 M Tris buffer containing 2% EDTA. After being 
shaken for 10 min, the alumina was sedimented by centrifugation and washed twice with 
deionized water. After the second wash, the alumina was resuspended in deionized water and 
transferred to a 2-μm-pore-size regenerated cellulose microfilter. The filter was centrifuged for 3 
min at low speed, and the filtrate was discarded. The filter was then transferred to a clean 
centrifuge tube, and catecholamines were eluted with 0.2 ml of 0.1 M perchloric acid. This eluate 
was injected directly onto the HPLC column. 
 
Chromatographic analysis was performed by using a BAS 400 liquid chromatography system 
with electrochemical detection utilizing a glassy carbon working electrode with an applied 
potential of +650 mV. The mobile phase consisted of 0.17 M monochloroacetic acid and 0.12 M 
NaOH containing 200 mg/l SDS. A BAS 3m Phase 11 ODS column (100 × 3.2 mm) was used 
and maintained at 30°C with a heater block. The solvent flow rate was 0.9 ml/min. Peak areas 
were quantified by using a Varian model 4270 integrator set to an attenuation of 16 and a chart 
speed of 0.5 cm/min. 
 
An internal standard dihydroxybenzylamine was used in the analysis, and the ratio of the area of 
the catecholamine peak to the area of the dihydroxybenzylamine peak was used to calculate the 
catecholamine concentrations. The limits of detectability for both Epi and NE were 136 pmol/l. 
The percent recovery for the extraction of NE and Epi was 85 and 77%, respectively. Epi and NE 
values were corrected for the internal standard. The within-day CVs for Epi and NE were 1.25 
and 3.7% respectively; the between-day CVs were 3.4 and 4.7%, respectively. This assay was 
sensitive enough to measure all resting and exercise catecholamine levels. 
 
Statistical analysis. ANOVA with repeated measures was used to determine whether the 
difference between the times of the plasma Epi or NE peak concentrations and the serum GH 
peak concentration was consistent, independently of exercise intensity. 
 
Separate regression models were estimated for each of the 10 study subjects with the incremental 
change in serum GH concentration (peak − baseline) regressed against 1) the change in plasma 
NE, 2) the change in plasma Epi (simple-regression models), and 3) the change in NE and Epi 
(multiple-regression model). 
 
The set of 10 slopes associated with the individual regression models was then evaluated by the 
Wilcoxon signed-rank test against a null hypothesis of a zero median slope for the group (17). 
 
RESULTS 
 
All data are presented as means ± SE. 
 
Subjects' V˙o2 at LT averaged 2.72 ± 0.18 l/min (32.6 ± 2.6 ml · kg−1 · min−1),V˙o2 peak was 3.93 
± 0.19 l/min (47.9 ± 2.2 ml · kg−1 · min−1), V˙o2 at LT/V˙o2 peak was 0.68 ± 0.4, and percent body 
fat was 19.3 ± 1.9%. As expected, V˙o2 at LT andV˙o2 peak were strongly correlated (r = 0.79) 
 
V˙o2 and blood lactate concentration during constant-load exercise. One-way ANOVA with 
repeated measures and post hoc analyses revealed that V˙o2 and blood lactate concentrations 
increased (P < 0.05) across exercise intensities. The mean V˙o2 at each exercise intensity was 
1.01 ± 0.08 l/min at 0.25LT, 1.85 ± 0.14 l/min at 0.75LT, 2.45 ± 0.18 l/min at LT, 2.98 ± 0.21 
l/min at 1.25LT, and 3.55 ± 0.31 l/min at 1.75LT. TheseV˙o2 values corresponded to 26, 47, 62, 
76, and 90% of V˙o2 peak, respectively. Whether data were examined relative to LT or relative 
toV˙o2 peak, linear increments in exercise intensity were observed. Mean blood lactate values were 
0.65 ± 0.05 mM at 0.25LT, 0.93 ± 0.11 mM at 0.75LT, 1.52 ± 0.16 mM at LT, 2.53 ± 0.40 mM 
at 1.25LT, and 4.94 ± 0.40 mM at 1.75LT (P < 0.05). These mean data as well as the 6-h GH 
data have been presented previously (29). 
 
 
Fig. 1. Serum growth hormone (GH; A) and plasma norepinephrine (NE; B) and epinephrine (Epi; C) concentrations 
during repetitive blood sampling over 6 h at rest (control) and during separate exercise sessions assigned with 
randomly ordered intensities of 0.25, 0.75, 1.0, 1.25, and 1.75 of the individual lactate threshold (LT). 0.25LT and 
0.75LT, 25 and 75% of the difference between the O2 uptake achieved at LT and the O2 uptake at rest; LT, at LT; 
1.25LT and 1.75LT, 25 and 75% of the difference between the O2 uptake achieved at LT and peak O2 uptake. 
Values are means ± SE; n = 10 men. Catecholamine values between 12:00 and 1:00 were negligible and are not 
shown. 
Figure 1 shows the mean serum GH (A), and plasma NE (B) and Epi (C) concentrations during 
blood sampling over 6 h during control, 0.25LT, 0.75LT, LT, 1.25LT, and 1.75LT conditions. A 
similar dose-response pattern was observed for GH and NE, in which increasing exercise 
intensity resulted in an increase in GH and NE. Although Epi rose with increasing exercise 
intensity, the effects of exercise intensity on Epi release were most pronounced when the 1.75LT 
intensity was reached. 
 
Table 1 shows peak concentrations of GH, NE, and Epi in relation to exercise intensities of 
0.25LT, 0.75LT, LT, 1.25LT, and 1.75LT. ANOVA revealed the following: 1) for peak GH, all 
exercise comparisons were significantly different with the exception of 0.25LT vs. 0.75LT, 
0.75LT vs. LT, and 1.25LT vs. 1.75LT;2) for peak NE, all exercise comparisons were 
significantly different with the exception of 0.25LT vs. 0.75LT and LT, 0.75LT vs. LT, and LT 
vs. 1.25LT; and 3) for peak Epi, the 1.75LT exercise condition was significantly different from 
all other exercise intensities, but no other exercise comparisons were different. Analysis of the 
sets of individual within-subject regression models revealed that peak GH, NE, and Epi 
increased significantly with each exercise intensity in a simple linear manner (P = 0.002,P = 
0.002, and P = 0.004, respectively). 
 
Table 1. Peak serum growth hormone and plasma norepinephrine and epinephrine 
concentrations attained over 6 h during 0.25LT, 0.75LT, LT, 1.25LT, and 1.75LT exercise 
conditions 
 
 
Table 2. Time to peak (from the onset of exercise) for serum growth hormone and plasma 
norepinephrine and epinephrine and the time delay between peak NE and EPI and peak GH 
 
 
Table 2 summarizes the times to peak for GH, NE, and Epi as well as the latency between peak 
NE or Epi and peak GH. The time to peak GH was not affected by exercise intensity, with the 
exception of the 0.25LT condition, in which time to peak GH was significantly greater than for 
all other exercise intensities. Peak plasma NE and Epi occurred 20 min after the onset of exercise 
in all subjects and always preceded peak GH. With the exception of the 0.25LT condition, 
intensity of exercise did not affect the time delay between peak NE or Epi and peak GH. 
 
The individual relationships between the increment (from baseline to peak) in GH vs. the change 
in NE and Epi are shown in Figs. 2 and 3, respectively. The group relationships are derived from 
the average of intercepts and slopes from within-subject regression results. With increasing 
exercise intensity, the change in GH was linearly related to the change in NE (P = 0.002) and to 
the change in Epi (P = 0.014). Multiple-regression analysis to account for NE and Epi covariance 
revealed that the GH rise associated with an increase in NE (P = 0.02) could not be explained by 
changes in Epi alone (P = 0.77); i.e., NE rises contributed independently to the GH incremental 
response. 
 
 
Fig. 2. Individual (and group, solid line) relationships between the incremental changes (from baseline to peak, Δ) in 
serum GH and plasma NE concentrations in 10 young men studied at different exercise intensities assigned in 
random order (Fig. 1). 
 
 
Fig. 3. Individual (and group, solid line) relationships between the incremental changes (from baseline to peak) in 
serum GH and plasma Epi concentrations in 10 young men studied at different exercise intensities assigned in 
random order (Fig. 1). 
 
DISCUSSION 
 
Although many clinical studies have attempted to discern the individual contributions of various 
neurotransmitters to exercise-induced GH release, no single mechanism has emerged as primary. 
Indeed, catecholamines, muscarinic agents, opiatergic pathways, GABA-ergic receptors, and so 
forth may all modify GH secretion (5, 11, 13,22, 25, 32). For example, available experimental 
evidence suggests that α2-adrenergic pathways may limit somatostatin release (15) and stimulate 
GH-releasing hormone release, thus triggering GH secretion. Conversely, β2-adrenergic agonists 
likely block GH secretion by eliciting somatostatin release (13). Although the effects of changing 
adrenergic activity on GH release during exercise are less well understood, blood concentrations 
of both Epi and NE rise with escalating exercise intensity (26, 28, 30,40). Catecholamines can 
directly stimulate GH secretion from rodent pituitary tissue in vitro (13). In addition, central 
nervous system hypothalamic adrenergic activity may modulate the exercise-driven release of 
GH. In support of the second notion, both nonselective (propranolol) and cardioselective 
(metoprolol) β1-adrenergic receptor blockers can significantly augment the GH response to 
exercise (34). Conversely, salbutamol and broxaterol (both selective β2-agonists) suppress the 
exercise-induced release of GH (12). Thus we postulate that exercise favors 1) an increase in 
stimulatory α2-adrenergic tone and 2) partial suppression of inhibitory β2-adrenergic tone. 
However, the effects of α-receptor blockade on exercise-stimulated GH are less clear, because 
not all papers report that phentolamine (a nonspecific α-receptor antagonist) suppresses GH 
release during exercise (14,24, 31). 
 
The present study shows that peripheral markers of heightened adrenergic outflow precede and 
are quantitative physiological correlates of exercise-intensity-dependent GH release in humans. 
First, peak plasma concentrations of NE and Epi always preceded maximal GH release. The 
zenith of NE and Epi in blood always occurred during the ongoing exercise stimulus, whereas 
peak serum GH concentrations developed toward the end of or after exercise. A wide range of 
intensities of exercise did not influence the time delay between peak NE or Epi and peak GH 
appearance in the blood (∼20 min), with the exception of the lowest exercise intensity of 
0.25LT. However, at the latter intensity, GH responses did not differ significantly from control 
(Fig. 1; P > 0.29). Second, with increasing exercise intensity, the increment (change from 
baseline to peak) in GH was linearly related to the increment in NE (P = 0.002) and that in Epi 
(P = 0.014) (Figs. 2 and 3). Multiple-linear regression analysis to allow for expected correlations 
between NE and Epi release revealed that the dominant relationship was between incremental 
changes in GH and NE (P = 0.02), rather than Epi (P = 0.77). We interpret these findings to 
indicate that higher exercise intensities may drive increased GH release in part by central 
adrenergic activation. It should be noted that, whereas NE and Epi were sampled every 20 min 
and GH every 10 min (to stay within institutional review board guidelines for blood withdrawal), 
partial censoring of the exact timing of the NE or Epi peaks would not influence their consistent 
appearance before GH (Fig.1A). In addition, the different distribution volumes for these analytes 
would not alter their strong linear relationships, because we regressed incremental NE or Epi 
against incremental GH release (Figs. 2 and 3). Nonetheless, hormone-specific deconvolution 
analysis to correct for unequal disappearance rates, if applied to even more intensively sampled 
time series, would likely portray the absolute latencies in endogenous appearance times even 
more accurately. 
 
Although not addressed by the present study, cholinergic, opiatergic, and other pathways can 
also modulate GH release. Cappa et al. (3) reported that pyridostigmine (an indirect cholinergic 
agonist) and exercise stimulated GH release additively. We corroborated that oral 
pyridostigmine, alone or in combination with the opiate receptor antagonist naltrexone, can 
potentiate exercise-induced GH release (33). In addition, although atropine (a muscarinic-
receptor blocker) inhibits the GH response to exercise (4), this agent also inhibits GH secretion 
in response to virtually all stimuli (13). The role of opioids in the control of exercise-induced GH 
release is more controversial. Moretti et al. (27) reported that high doses of naloxone (an opiate-
receptor antagonist) completely blocked exercise-induced GH release in well-trained competitive 
athletes. In contrast, Coiro et al. (9) and analyses from our laboratory (33) noted that naloxone 
and naltrexone, respectively, did not inhibit exercise-stimulated GH release in subjects who were 
not trained athletes. Naltrexone also did not alter the rise in GH concentrations stimulated by 
pyridostigmine (33), which would speak against a major interaction between opiatergic and 
cholinergic pathways in the exercise effect (33). 
 
In conclusion, the present analysis of the intensity-dependent effects of a physiological exercise 
stimulus identifies precedent and proportionate increases in markers of central adrenergic 
outflow and exercise-induced GH release in young men. Comodulatory effects of cholinergic 
and/or opiatergic signals are not excluded by these findings. Indeed, exercise may alter the 
activity of several neurotransmitter pathways concurrently or in succession (13). 
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